Please provide your email address to receive an email when new articles are posted on . New Pan American League of Associations for Rheumatology recommendations include remission maintenance ...

PHILADELPHIA -- Rituximab (Rituxan) matched IV cyclophosphamide for improving lung function in patients with interstitial lung disease (ILD) related to systemic sclerosis and other connective tissue ...

Patients undergoing matched-donor stem cell transplants lived four times longer without episodes of graft-versus-host disease (GVHD) with post-transplant cyclophosphamide-cyclosporin prophylaxis, a ...

Please provide your email address to receive an email when new articles are posted on . Week-22 remission rates were 81% among patients using infliximab and 56% in those on cyclophosphamide. Mild to ...

Uppsala, Sweden - The risk of bladder cancer rises steadily with increasing cumulative dose of cyclophosphamide in patients with Wegener's granulomatosis (WG), although some of this risk is ...

Bortezomib is a potent first-in-class proteasome inhibitor. 15 In a pivotal large phase-III study in relapsed MM, bortezomib proved superior to dexamethasone in both event-free and overall survival. 4 ...

Post–hematopoietic cell transplantation (HCT) prophylaxis using cyclophosphamide to stave off graft-vs-host disease had positive results compared with calcineurin inhibitor–based prophylaxis, ...

Clinical Characteristics and Outcomes of Caribbean Patients With Adult T-Cell Lymphoma/Leukemia at Two Affiliated New York City Hospitals Twenty patients (17 with platinum-resistant and 3 with ...

Cyclophosphamide is widely used to treat severe manifestations of numerous autoimmune rheumatic diseases including systemic sclerosis. Based on recent data, immunological and inflammatory activation ...

LINCOLNSHIRE, Ill., April 06, 2026--(BUSINESS WIRE)--Nexus Pharmaceuticals, LLC announces the launch of Cyclophosphamide Injection, available in ready to dilute 2.5 mL fill and 5 mL fill multiple-dose ...